Value of serum apolipoprotein E combined with lipoprotein-associated phospholipase A2 levels in evaluating the severity of preeclampsia
WU Quan CHENG Jin
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui University of Science and Technology Huainan First People’s Hospital, Anhui Province, Huainan 232000, China
Abstract:Objective To explore the value of serum apolipoprotein E (ApoE) combined with lipoprotein-associated phospholipase A2 (Lp-PLA2) levels in evaluating the severity of preeclampsia. Methods The clinical data of 101 cases of preeclampsia patients admitted to the First Affiliated Hospital of Anhui University of Science and Technology from January 2020 to October 2022 were collected. They were divided into mild group and severe group according to the severity of the disease. The serum ApoE and Lp-PLA2 levels of patients were detected; the factors affecting the severity of the preeclampsia patients were analyzed by logistic regression; the value of serum ApoE combined with Lp-PLA2 levels in evaluating the severity of preeclampsia was analyzed by receiver operating characteristic curve. Results Among the 101 cases of preeclampsia, 78 cases were mild, 23 cases were severe. The proportion of hypertension, serum ApoE and Lp-PLA2 levels in severe group were higher than those in mild group (P<0.05). Serum ApoE and Lp-PLA2 levels were independent risk factors for the severity of preeclampsia (OR=3.282, 2.772, P<0.05). The area under the curve of serum ApoE combined with Lp-PLA2 to assess the severity of preeclampsia was higher than that detected by each indicator alone. Conclusion Serum ApoE and Lp-PLA2 levels in patients with preeclampsia are related to the severity of the disease, and their combined diagnosis value is high.
吴泉 程锦. 血清载脂蛋白E联合脂蛋白相关磷脂酶A2水平对子痫前期严重程度的评估价值[J]. 中国医药导报, 2023, 20(32): 108-111.
WU Quan CHENG Jin. Value of serum apolipoprotein E combined with lipoprotein-associated phospholipase A2 levels in evaluating the severity of preeclampsia. 中国医药导报, 2023, 20(32): 108-111.